Pasithea Therapeutics Corp. (KTTA) Stock Analysis & Investment Frameworks
Pasithea Therapeutics Corp. (KTTA) stock analysis on Invetso. Review Pasithea Therapeutics Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pasithea Therapeutics Corp. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Pasithea Therapeutics Corp. Key Financial Metrics
- Market Cap: $16.30M
- Revenue: $N/A
- ROE: -49.49%
- ROIC: -48.04%
- Dividend Yield: N/A
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Pasithea Therapeutics Corp. Investment Frameworks
Invetso analyzes Pasithea Therapeutics Corp. (KTTA) across the following frameworks:
- Pasithea Therapeutics Corp. 10Y Growth Potential
- Pasithea Therapeutics Corp. Scenario Analysis
- Pasithea Therapeutics Corp. Risks & Opportunities
- Pasithea Therapeutics Corp. Economic Moat
- Pasithea Therapeutics Corp. Business Model
- Pasithea Therapeutics Corp. Management
- Pasithea Therapeutics Corp. SWOT Analysis
- Pasithea Therapeutics Corp. Porter's 5 Forces
- Pasithea Therapeutics Corp. PESTLE Analysis
- Pasithea Therapeutics Corp. ESG Analysis